热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Alexa Fluor® 488 anti-mouse CD8a Antibody
产品名称：
Alexa Fluor® 488 anti-mouse CD8a Antibody
产品类别：
抗体
产品编号：
100726
产品应用：
100726
[价格]
规格 价格 库存
25µg ￥ 432 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 488 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
3D IHC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 106 cells in 100 ?l volume. For 3D immunohistochemistry on formalin-fixed tissues, a concentration of 5.0 ?g/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 488 has a maximum emission of 519 nm when it is excited at 488 nm.


Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  30. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  2. Moderzynski K, et al. 2016. PLoS Negl Trop Dis. . PubMed
  3. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  4. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  5. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  6. Suzuki K, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:119. PubMed
  7. Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed
  8. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  9. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  10. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  11. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  12. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
  13. Onishi S, et al. 2015. PLoS One. 10:126564. PubMed
  14. Tang B, et al. 2020. Clin Cancer Res. 26:2216. PubMed
  15. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  16. Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed
  17. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  18. Yang H, et al. 2015. Cancer Res . 75: 3812-3822. PubMed
  19. An J, et al. 2022. iScience. 25:103570. PubMed
  20. Bartkowiak T, et al. 2015. Proc Natl Acad Sci U S A. 112: 5290-5299. PubMed
  21. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  22. Xiao Y, et al. 2021. Cancer Cell. 39(3):423-437.e7. PubMed
  23. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  24. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  25. Chen C, et al. 2019. Cell Rep. 29:4200. PubMed
  26. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  27. Yamada T, et al. 2016. J Immunol. 197: 4079 - 4089. PubMed
  28. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  29. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  30. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  31. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  32. Kim S, et al. 2021. Elife. 10:. PubMed
  33. Ma S, et al. 2022. Cell Rep. 38:110520. PubMed
  34. Mantilla-Rojas C, et al. 2022. Cancers (Basel). 14:. PubMed
  35. Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed
  36. Collins N, et al. 2016. Nat Commun. 7:11514. PubMed
  37. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  38. Sun J, et al. 2020. Cell. 182:734. PubMed
  39. Lee C, et al. 2009. Clin Cancer Res. 2.538888889. PubMed
  40. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  41. Kaddatz H, et al. 2020. Glia. 69:925. PubMed
  42. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  43. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  44. Chen ST et al. 2019. Cell host & microbe. 25(4):602-616 . PubMed
  45. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  46. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  47. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  48. Klose R, et al. 2016. Nat Commun. 7:12528. PubMed
  49. Zhu J et al. 2017. Cell stem cell. 20(3):374-384 . PubMed
  50. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  51. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  52. Simula L, et al. 2022. Mol Oncol. 16:188. PubMed
  53. Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed
  54. Conforti A, et al. 2021. Mol Ther. S1525-0016:00466. PubMed
  55. Simula L, et al. 2020. Cell Death Differ. 27:2749. PubMed
RRID
AB_493423 (BioLegend Cat. No. 100726) AB_389304 (BioLegend Cat. No. 100723)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线